Laboratory Surveillance
Laboratory Surveillance datasets in the CDC Open Data Catalog
This page contains all datasets in the Laboratory Surveillance category of the CDC Open Data Catalog.
Total Datasets in Category: 8 Last Updated: 07/14/2025
Percent Positivity of COVID-19 Nucleic Acid Amplification Tests by HHS Region, National Respiratory and Enteric Virus Surveillance System
Description: More than 450 public health and clinical laboratories located throughout the United States participate in surveillance for severe acute respiratory virus coronavirus type 2 (SARS-CoV-2), the virus that causes COVID-19, through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). The dataset contains a weekly summary of aggregate counts of the total SARS-CoV-2 tests and SARS-CoV-2 detections reported to NREVSS since March 14, 2020. These data are reported weekly on a voluntary basis. Clinical laboratories do not report demographic data through NREVSS. Testing practices may vary regionally, and the number of participating laboratories may change from year to year. Results can be changed for up to 2 years after the initial reporting week. However, discrepancies may be noted and updated at the discretion of the data stewards and key stakeholders. While NREVSS strives to present the most precise estimates of respiratory viral trends with reporting burden minimized for participating laboratories, there are several inherent limitations to this surveillance system. NREVSS does not collect patient-specific data or demographic information. Multiple samples may be collected from a single patient, so NREVSS results do not necessarily reflect the number of patients tested, nor do they directly reflect hospitalizations or deaths related to COVID-19. Participating laboratories vary in size, testing capabilities, and areas served. Some institutions may receive and test samples from sites across a given state or even from multiple states. Without direct knowledge of the population base, NREVSS cannot be used to determine the prevalence or incidence of infection. For more information on NREVSS and COVID-19 surveillance please visit: https://www.cdc.gov/surveillance/nrevss. These data appear starting May 25, 2023 on the CDC COVID Data Tracker at the following URLs: https://covid.cdc.gov/covid-data-tracker/#trends ; https://covid.cdc.gov/covid-data-tracker/#cases. NREVSS data are reported at the national and HHS regional levels. The ten (10) U.S. Department of HHS regions are defined here: https://www.hhs.gov/about/agencies/iea/regional-offices/index.html. The data represent SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) results, which include reverse transcriptase-polymerase chain reaction (RT-PCR) tests from a voluntary, sentinel network of participating laboratories in the United States, including clinical, public health and commercial laboratories (https://www.cdc.gov/surveillance/nrevss/labs/index.html). These data exclude antigen, antibody, and at-home test results. All data are provisional and subject to change. Reporting is less complete for the past 1 week, and more complete (>90%) for the period 2 weeks earlier. There are data from all states across the 10 HHS regions. Because the data are from a sentinel network of laboratories, however, results may vary geographically. The data do not include all test results within a jurisdiction and therefore do not reflect all SARS-CoV-2 NAATs administered in the United States. Percent positivity is one of the surveillance metrics used to monitor COVID-19 transmission over time and by area. Percent positivity is calculated by dividing the number of positive NAATs by the total number of NAATs administered, then multiplying by 100 [(# of positive NAAT tests / total NAAT tests) x 100]. The data represent laboratory tests performed, not individual (deduplicated) results in people. In the table and upon hovering on the map, the total test counts in the data reflect the latest data reported from NREVSS laboratories and may not match the data presented by various jurisdictions. On May 11, 2023, CDC discontinued utilizing the COVID electronic laboratory reporting (CELR) platform as the primary laboratory source of COVID-19 results. These data are archived at health.data.gov. For more information about NREVSS, please see: https://www.cdc.gov/surveillance/nrevss/
Schema: dwv_lab_surveillance
Table Name: covid19_positivity_nrvss_hhs_region_xpl__gvsb_yw6g
Dataset ID: gvsb-yw6g
Category: Laboratory Surveillance
Tags: test, covid19, nrevss
Source Data: https://data.cdc.gov/d/gvsb-yw6g
2022–2023 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates
Description: CDC is collaborating with Vitalant Research Institute, American Red Cross, and Westat Inc. to conduct a nationwide COVID-19 seroprevalence survey of blood donors. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection and refers to the percent of the population with anti-nucleocapsid antibodies. Combined infection-Induced and Vaccination-Induced seroprevalence estimates the proportion of the population with antibody evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both, and refers to the percent of the population that has anti-spike antibodies, anti-nucleocapsid antibodies, or both. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence-2022
Schema: dwv_lab_surveillance
Table Name: nationwide_blood_donor_seroprevalence_s__ar8q_3jhn
Dataset ID: ar8q-3jhn
Category: Laboratory Surveillance
Tags: coronavirus, covid, covid19, covid-19, laboratory, ncird-corvd, prevalence, sars-cov, seroprevalence, serosurveys
Source Data: https://data.cdc.gov/d/ar8q-3jhn
2020-2021 Nationwide Blood Donor Seroprevalence Survey Infection-Induced Seroprevalence Estimates
Description: CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection and refers to the prevalence of the population with both anti-S and anti-N antibodies. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html
Schema: dwv_lab_surveillance
Table Name: nationwide_blood_donor_seroprevalence_s__mtc3_kq6r
Dataset ID: mtc3-kq6r
Category: Laboratory Surveillance
Tags: coronavirus, covid, covid19, covid-19, laboratory, ncird-corvd, prevalence, sars-cov, seroprevalence, serosurveys
Source Data: https://data.cdc.gov/d/mtc3-kq6r
2020-2021 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates
Description: CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Combined seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both. It estimates the proportion of the population with some presumed protection against infection with the virus that causes COVID-19. The term “combined seroprevalence” refers to the combined infection- and vaccination-induced SARS-CoV-2 seroprevalences. This is the population that has anti-S antibodies, regardless of the presence of anti-N antibodies. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html
Schema: dwv_lab_surveillance
Table Name: nationwide_blood_donor_seroprevalence_s__wi5c_cscz
Dataset ID: wi5c-cscz
Category: Laboratory Surveillance
Tags: coronavirus, covid, covid19, covid-19, laboratory, ncird-corvd, prevalence, sars-cov, seroprevalence, serosurveys
Source Data: https://data.cdc.gov/d/wi5c-cscz
Nationwide Commercial Laboratory Seroprevalence Survey
Description: CDC is working with commercial laboratories to conduct large-scale geographic seroprevalence surveys to estimate the percentage of people who were previously infected with SARS-CoV-2, the virus that causes COVID-19 disease. The strategy involves working with state, local, territorial, academic, and commercial partners to better understand COVID-19 in the United States using serology (antibody) testing for surveillance (“seroprevalence surveys” or “serosurveys”). For the surveys, de-identified clinical blood samples are tested for antibodies to SARS-CoV-2. This dataset contains the data used to by the Nationwide Commercial Laboratory Seroprevalence Survey interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#national-lab. Additional information is available at https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html.
Schema: dwv_lab_surveillance
Table Name: nationwide_commercial_laboratory_seropr__d2tw_32xv
Dataset ID: d2tw-32xv
Category: Laboratory Surveillance
Tags: coronavirus, covid, covid19, covid-19, laboratory, ncird-corvd, prevalence, seroprevalence, serosurveys
Source Data: https://data.cdc.gov/d/d2tw-32xv
Respiratory Syncytial Virus Laboratory Data (NREVSS)
Description: Approximately 600 public health and clinical laboratories located throughout the United States, participate in surveillance for respiratory syncytial virus (RSV) through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS). The dataset contains a weekly summary of the total RSV tests and RSV detections reported to NREVSS. These data are reported on a voluntary basis. Clinical laboratories do not report demographic data through NREVSS. Testing practices and the number of participating laboratories may change from year to year. Results can be changed two years after the initial reporting week. However, discrepancies may be noted and updated at the discretion of the data stewards and key stakeholders. Data are collected from collaborating university and community hospital laboratories, select states and county public health laboratories, and commercial laboratories. This information is submitted and updated on a weekly basis. While NREVSS strives to present the most precise national, regional and state respiratory viral trends with the least amount of burden possible for participating laboratories, there are a number of inherent limitations to this surveillance system. NREVSS does not collect patient-data or demographic information. Multiple samples may be collected from a single patient, so NREVSS results do not necessarily reflect the number of patients tested nor does it reflect hospitalizations or deaths related to a particular virus. Participating laboratories vary in size, testing capabilities, and areas served. Some institutions may receive and test samples from sites across a given state or even from multiple states. Without direct knowledge of the population base, NREVSS cannot be used to determine the prevalence or incidence of infection. For more information on RSV surveillance and research please visit: https://www.cdc.gov/surveillance/nrevss and https://www.cdc.gov/rsv/research/us-surveillance.html
Schema: dwv_lab_surveillance
Table Name: respiratory_syncytial_virus_lab_data_re__52kb_ccu2
Dataset ID: 52kb-ccu2
Category: Laboratory Surveillance
Tags: ari, bronchiolitis, bronchitis, lri, nrevss
Percent Positivity of Respiratory Syncytial Virus Nucleic Acid Amplification Tests by HHS Region, National Respiratory and Enteric Virus Surveillance System
Description: More than 450 public health, clinical, and commercial laboratories located throughout the United States voluntarily participate in surveillance for respiratory syncytial virus (RSV) through CDC's National Respiratory and Enteric Virus Surveillance System (NREVSS) (https://www.cdc.gov/surveillance/nrevss/labs/index.html). The data contain weekly, aggregate counts of RSV tests performed and RSV detections as reported to NREVSS since April 11, 2020. NREVSS data are reported weekly at the national and 10 HHS regional levels (https://www.hhs.gov/about/agencies/iea/regional-offices/index.html). The presented data are RSV Nucleic Acid Amplification Test (NAAT) results, which include reverse transcription-polymerase chain reaction (RT-PCR) tests. These data exclude antigen, antibody, and at-home test results. Less than 5% of RSV tests reported to NREVSS are from antigen tests. All data are provisional and subject to change. Reporting is less complete for the most recent weeks, but relatively complete (>90%) for the period up to 2 weeks earlier. Percent positivity is a surveillance metric used to monitor RSV activity over time and by geographic area. Participating laboratories send weekly reports of the total number of RSV tests performed that week, and the number of those tests that were positive. In the table and upon hovering on the map, the total test counts reflect the latest data reported to NREVSS and may differ from data presented by public health jurisdictions. Public health jurisdictions may have additional data not reported to NREVSS and may use a different reporting cadence. The RSV trend graphs display the weekly average percent of tests positive for RSV among all the tests performed. Each point on the regional table displays the average number of RSV tests that were performed, and the average percent of those that were positive during a 3-week period (i.e., the specified week, and the weeks immediately preceding and following it). This is also known as a centered, 3-week moving average. The RSV detections displayed are the 5-week moving average (average of the 4 previous and current weeks) in accordance with the recommendations for assessing RSV trends by detections (https://academic.oup.com/jid/article/216/3/345/3860464). NREVSS strives to present precise estimates of respiratory viral trends and minimize reporting burden for participating laboratories. However, there are several limitations to this surveillance system. NREVSS is a laboratory-based surveillance system that does not have patient-specific data; multiple tests from a single patient may be included. In addition, NREVSS does not collect demographic or clinical data (i.e., hospitalizations or deaths). Testing practices may vary regionally, and the number of participating laboratories may change from year to year. Laboratories from all 50 states report data weekly, but reporting is voluntary and may not be representative of local RSV activity. The data do not include all test results within a jurisdiction and therefore do not reflect all RSV NAATs administered regionally or nationally. Participating laboratories vary in size, testing capabilities, and areas and populations served. Geographic results from clinical laboratories are based on testing location and laboratories may test samples from across one or more states. For more information on NREVSS and RSV surveillance please visit: https://www.cdc.gov/surveillance/nrevss.
Schema: dwv_lab_surveillance
Table Name: respiratory_syncytial_virus_positivity___3cxc_4k8q
Dataset ID: 3cxc-4k8q
Category: Laboratory Surveillance
Tags: chronic lower respiratory disease, rsv, respiratory syncytial virus, respiratory disease
Source Data: https://data.cdc.gov/d/3cxc-4k8q
SARS-CoV-2 Variant Proportions
Description: To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC's national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. Viral genomic sequences are analyzed and classified as a particular variant. The proportions of variants in a population are estimated nationally, by HHS region, and by jurisdiction. The thousands of sequences analyzed every week through CDC’s national genomic sequencing and bioinformatics efforts fuel this comprehensive and population-based U.S. surveillance system established to identify and monitor the spread of variants. These data appear on the CDC COVID Data Tracker at the following URL: https://covid.cdc.gov/covid-data-tracker/#variant-proportions For more information on how these data are generated and used to provide estimates of variant proportions, please see the following references:
Paul P, France AM, Aoki Y, et al. Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, December 2020–May 2021. MMWR Morb Mortal Wkly Rep 2021;70:846–850. DOI: http://dx.doi.org/10.15585/mmwr.mm7023a3
Lambrou AS, Shirk P, Steele MK, et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:206–211. DOI: http://dx.doi.org/10.15585/mmwr.mm7106a4
Schema: dwv_lab_surveillance
Table Name: sarscov2_variant_proportions__jr58_6ysp
Dataset ID: jr58-6ysp
Category: Laboratory Surveillance
Tags: sars-cov-2, variant surveillance, variant proportion, surveillance, nowcasting, covid-19
Source Data: https://data.cdc.gov/d/jr58-6ysp
Last updated